| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24049 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab (Keytruda®) in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy. |
| Rapid review commissioned |
04/12/2024 |
| Rapid review completed |
10/01/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/01/2025 |
| Pre-submission consultation with Applicant |
24/02/2025 |
